{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:00:04Z","timestamp":1763766004108,"version":"3.40.4"},"reference-count":62,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.bbr.2013.03.027","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T05:02:07Z","timestamp":1364274127000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism"],"prefix":"10.1016","volume":"247","author":[{"given":"M.","family":"Horiguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1176\/jnp.3.3.269","article-title":"Attention and higher cortical functions in schizophrenia","volume":"3","author":"Kenny","year":"1991","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"7","key":"10.1016\/j.bbr.2013.03.027_bib0010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/archpsyc.1991.01810310036007","article-title":"Neuropsychological function in schizophrenia. Selective impairment in memory and learning","volume":"48","author":"Saykin","year":"1991","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.bbr.2013.03.027_bib0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1016\/j.bbr.2013.03.027_bib0020","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.nlm.2011.04.006","article-title":"Declarative memory deficits and schizophrenia: problems and prospects","volume":"96","author":"Stone","year":"2011","journal-title":"Neurobiology of Learning and Memory"},{"issue":"6","key":"10.1016\/j.bbr.2013.03.027_bib0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.bbr.2013.03.027_bib0035","doi-asserted-by":"crossref","unstructured":"Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 1993;34:702\u201312.","DOI":"10.1016\/0006-3223(93)90043-D"},{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2013.03.027_bib0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/schbul\/sbq038","article-title":"The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?","volume":"37","author":"Buchanan","year":"2011","journal-title":"Schizophrenia Bulletin"},{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/schbul\/23.3.437","article-title":"Functional and anatomical aspects of prefrontal pathology in schizophrenia","volume":"23","author":"Goldman-Rakic","year":"1997","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Research"},{"issue":"4\u20136","key":"10.1016\/j.bbr.2013.03.027_bib0060","first-page":"365","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cellular and Molecular Neurobiology"},{"issue":"10","key":"10.1016\/j.bbr.2013.03.027_bib0065","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/hrp.7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1999","journal-title":"Harvard Review of Psychiatry"},{"issue":"4","key":"10.1016\/j.bbr.2013.03.027_bib0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbr.2013.03.027_bib0080","doi-asserted-by":"crossref","unstructured":"Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20(2):106-118.","DOI":"10.1016\/S0893-133X(98)00067-0"},{"key":"10.1016\/j.bbr.2013.03.027_bib0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.brainresrev.2008.07.006","article-title":"The acute effects of NMDA antagonism: from the rodent to the human brain","volume":"60","author":"Gunduz-Bruce","year":"2009","journal-title":"Brain Research Reviews"},{"issue":"4","key":"10.1016\/j.bbr.2013.03.027_bib0095","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.pnpbp.2009.03.013","article-title":"Disruptions in spatial working memory, but not short-term memory, induced by repeated ketamine exposure","volume":"33","author":"Enomoto","year":"2009","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"issue":"2-3","key":"10.1016\/j.bbr.2013.03.027_bib0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00213-010-2137-8","article-title":"The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment","volume":"213","author":"Meltzer","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2013.03.027_bib0110","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.neuropsychologia.2010.01.023","article-title":"Implications of animal object memory research for human amnesia","volume":"48","author":"Winters","year":"2010","journal-title":"Neuropsychologia"},{"issue":"10","key":"10.1016\/j.bbr.2013.03.027_bib0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1101\/lm.026070.112","article-title":"Restoration of dopamine release deficits during object recognition memory acquisition attenuates cognitive impairment in a triple transgenic mice model of Alzheimer's disease","volume":"19","author":"Guzm\u00e1n-Ramos","year":"2012","journal-title":"Learning and Memory"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-3565(25)10246-2","article-title":"Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties","volume":"264","author":"Oka","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"7","key":"10.1016\/j.bbr.2013.03.027_bib0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.bbr.2013.03.027_bib0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","article-title":"Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial","volume":"33","author":"Yang","year":"2010","journal-title":"Clinical Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.bbr.2013.03.027_bib0135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejphar.2010.11.023","article-title":"Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex","volume":"653","author":"Ohoyama","year":"2011","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0140","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0022-3565(25)38164-4","article-title":"Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and\/or adverse side-effects","volume":"265","author":"Noda","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.pbb.2010.04.027","article-title":"Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist","volume":"96","author":"Ohno","year":"2010","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00001756-200302100-00023","article-title":"Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice","volume":"14","author":"Nagai","year":"2003","journal-title":"Neuroreport"},{"issue":"5","key":"10.1016\/j.bbr.2013.03.027_bib0155","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1476-5381.1995.tb15106.x","article-title":"Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia","volume":"116","author":"Noda","year":"1995","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0160","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2 (Suppl.)","key":"10.1016\/j.bbr.2013.03.027_bib0165","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1016\/S0893-133X(99)00046-9","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/026988110101500108","article-title":"The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?","volume":"15","author":"Bantick","year":"2001","journal-title":"Journal of Psychopharmacology"},{"issue":"7","key":"10.1016\/j.bbr.2013.03.027_bib0175","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: Rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0180","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004714-200006000-00019","article-title":"Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia","volume":"20","author":"Sumiyoshi","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2013.03.027_bib0185","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1176\/appi.ajp.158.10.1722","article-title":"Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment","volume":"158","author":"Sumiyoshi","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"10","key":"10.1016\/j.bbr.2013.03.027_bib0190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0006-3223(00)01025-8","article-title":"The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia","volume":"49","author":"Sumiyoshi","year":"2001","journal-title":"Biological Psychiatry"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-011-2561-4","article-title":"The role of 5-HT(1A) receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats","volume":"221","author":"Horiguchi","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.bbr.2013.03.027_bib0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0014-2999(98)00483-X","article-title":"Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study","volume":"355","author":"Newman-Tancredi","year":"1998","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0205","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.bbr.2013.03.027_bib0210","doi-asserted-by":"crossref","unstructured":"Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research 2007;184(1):31\u20138.","DOI":"10.1016\/j.bbr.2007.06.012"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0215","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0014-2999(91)90414-L","article-title":"The involvement of dopamine D1 and D2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine","volume":"196","author":"Ellenbroek","year":"1991","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0220","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0022-3565(25)38100-0","article-title":"Serotonergic involvement in haloperidol-induced catalepsy","volume":"265","author":"Neal-Beliveau","year":"1993","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0225","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-011-2251-2","article-title":"Interaction of mGlu2\/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats","volume":"217","author":"Horiguchi","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.bbr.2013.03.027_bib0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2008.08.026","article-title":"5-HT7 receptor stimulation by 8-OH-DPAT counteracts the impairing effect of 5-HT(1A) receptor stimulation on contextual learning in mice","volume":"596","author":"Eriksson","year":"2008","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0235","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biological Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.bbr.2013.03.027_bib0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00213-008-1240-6","article-title":"Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors","volume":"202","author":"Nagai","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbr.2013.03.027_bib0245","unstructured":"Nakako T, Murai T, Ikejiri M, Ikeda K, Baba S, Ono M, et al. The effect of co-administration of tandospirone to typical and atypical antipsychotics on executive function in common marmoset object retrieval with detour (ORD). Neuroscience 2012 Annual Meeting (New Orleans) Poster Number 696.01; 2012 [abstract]."},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hup.1276","article-title":"Effect of blonanserin on cognitive function in antipsychotic-na\u00efve first-episode schizophrenia","volume":"27","author":"Tenjin","year":"2012","journal-title":"Human Psychopharmacology"},{"issue":"10","key":"10.1016\/j.bbr.2013.03.027_bib0255","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/npp.2012.64","article-title":"Prevention of the phencyclidine-induced impairment in novel object recognition in Female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist","volume":"37","author":"Horiguchi","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.bbr.2013.03.027_bib0260","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0197-0186(01)00079-1","article-title":"Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex","volume":"40","author":"Yoshino","year":"2002","journal-title":"Neurochemistry International"},{"issue":"8","key":"10.1016\/j.bbr.2013.03.027_bib0265","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","article-title":"Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors","volume":"160","author":"Llad\u00f3-Pelfort","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0270","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(97)81951-6","article-title":"Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation","volume":"338","author":"Rollema","year":"1997","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.bbr.2013.03.027_bib0275","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1046\/j.1471-4159.2001.00154.x","article-title":"5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release","volume":"76","author":"Ichikawa","year":"2001","journal-title":"Journal of Neurochemistry"},{"issue":"7","key":"10.1016\/j.bbr.2013.03.027_bib0280","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/WNR.0b013e328352de40","article-title":"5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux","volume":"23","author":"Huang","year":"2012","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbr.2013.03.027_bib0285","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","article-title":"Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens","volume":"288","author":"Kuroki","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.bbr.2013.03.027_bib0290","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1460-9568.2009.07042.x","article-title":"Qualitatively different modes of perirhinal-hippocampal engagement when rats explore novel vs. familiar objects as revealed by c-Fos imaging","volume":"31","author":"Albasser","year":"2010","journal-title":"European Journal of Neuroscience"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0295","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0028-3908(01)00054-5","article-title":"SB-243213: a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety","volume":"41","author":"Wood","year":"2001","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.bbr.2013.03.027_bib0300","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1254\/fpj.132.351","article-title":"Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia","volume":"132","author":"Ishibashi","year":"2008","journal-title":"Nippon Yakurigaku Zasshi - Folia Pharmacologica Japonica"},{"issue":"2","key":"10.1016\/j.bbr.2013.03.027_bib0305","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-HT7 receptors in the phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"3","key":"10.1016\/j.bbr.2013.03.027_bib0310","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1037\/a0023165","article-title":"Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders","volume":"125","author":"Gamo","year":"2011","journal-title":"Behavioral Neuroscience"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281300168X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281300168X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T02:01:14Z","timestamp":1745978474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643281300168X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":62,"alternative-id":["S016643281300168X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2013.03.027","relation":{},"ISSN":["0166-4328"],"issn-type":[{"type":"print","value":"0166-4328"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: Role of indirect 5-HT1A partial agonism","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2013.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}